Tags : FeDeriCa Study

Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab)

Tuba Khan December 12, 2019

Shots: The P-III FeDeriCa study involves assessing of SC inj. of Perjeta + Herceptin + CT vs IV infusion of Perjeta + Herceptin + CT in 500 patients with HER2+ […]readmore

Pharma

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination

Tuba Khan September 13, 2019

Shots: The P-III FeDeriCa study involves assessing of Perjeta (pertuzumab) and Herceptin (trastuzumab) as FDC in SC formulation + CT (IV) vs its standard IV Infusion formulation + CT in […]readmore

Tags : FeDeriCa Study

Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab)

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : FeDeriCa Study

Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab)

﻿Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination